Ultragenyx Pharmaceutical Divests Priority Review Voucher for $203 Million

The voucher, known as a PRV, was awarded to the company alongside the FDA approval of Fayuvi, or rebisufligene etisparvovec-hopf. This specific treatment targets mucopolysaccharidosis type IIIA, a rare and severe metabolic disorder. Priority review vouchers allow companies to expedite the regulatory timeline for a future drug candidate, making them highly liquid assets in the pharmaceutical industry.

Finalization of the sale remains subject to standard closing conditions. This includes the expiration of the mandatory waiting period required under the Hart-Scott Rodino Antitrust Improvements Act, which governs the competitive impact of corporate mergers and asset acquisitions.